Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Yuman Fong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8934-9959; OpenAlex author ID A5005824918. Sources: OpenAlex.

Their work

Papers
31 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
77
Papers, trials and grants by year

2011: 1 paper · 2012: 7 papers · 2013: 2 papers · 2014: 2 papers · 2015: none · 2016: 5 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 31

  1. The Best Patients for Effective Radiation of Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.3702↗
  2. CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model. Co-author DOI 10.1016/j.biopha.2025.118408↗
  3. Robotic pancreatectomy for pancreatic adenocarcinoma: evolving trends in patient selection and practice patterns across a decade. Co-author DOI 10.1016/j.hpb.2025.06.009↗
  4. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell … Last author DOI 10.1097/xcs.0000000000000964↗
  5. Robotic versus laparoscopic distal pancreatectomy for pancreatic adenocarcinoma in obese patients. Co-author DOI 10.1002/rcs.2596↗
  6. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-a… Co-author DOI 10.1016/j.omto.2021.12.022↗
  7. Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer. Co-author DOI 10.1016/j.omto.2022.02.022↗
  8. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Co-author DOI 10.1038/s41417-021-00350-4↗
  9. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Last author DOI 10.1016/j.jamcollsurg.2019.12.027↗
  10. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  11. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis. Last author DOI 10.1002/cam4.2491↗
  12. Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-27649-x↗
  13. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. Co-author DOI 10.1186/s12967-018-1483-x↗
  14. Accelerating progress in the fight against pancreatic cancer Proceedings of the 2017 Leo and Anne Albert Symposium for Pancreatic Cancer Research. Last author DOI 10.1002/jso.24672↗
  15. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24125↗
  16. Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. Co-author DOI 10.1007/s00520-016-3155-9↗
  17. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1007/s11605-015-3057-z↗
  18. Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. Last author DOI 10.1016/j.ebiom.2016.03.043↗
  19. Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virot… Last author DOI 10.1038/mto.2016.8↗
  20. Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.11.007↗
  21. Oncolytic viral therapy for pancreatic cancer: current research and future directions. Co-author DOI 10.2147/ov.s53858↗
  22. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? Co-author DOI 10.1007/s11605-012-2071-7↗
  23. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Co-author DOI 10.1111/hpb.12033↗
  24. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? Co-author DOI 10.1111/j.1477-2574.2012.00477.x↗
  25. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Co-author DOI 10.1158/0008-5472.can-12-0764↗
  26. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Co-author DOI 10.1245/s10434-011-1900-3↗
  27. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Co-author DOI 10.1245/s10434-011-2156-7↗
  28. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2301-y↗
  29. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. Co-author DOI 10.1371/journal.pone.0040157↗
  30. A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cance… Last author DOI 10.2967/jnumed.112.105056↗
  31. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcin… Co-author DOI 10.1097/sla.0b013e318214bcb4↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laleh Golkar Melstrom · 5 shared papers, 2017–2026 · strength 1.28
  2. Sang‐In Kim · 7 shared papers, 2018–2025 · strength 1.07
  3. Yanghee Woo · 7 shared papers, 2018–2025 · strength 0.94
  4. Zhifang Zhang · 5 shared papers, 2020–2025 · strength 0.77
  5. Susanne Gray Warner · 6 shared papers, 2018–2022 · strength 0.71
  6. Courtney Chen · 2 shared papers, 2024–2025 · strength 0.47
  7. Peter J. Allen · 11 shared papers, 2011–2016 · strength 0.42
  8. William R. Jarnagin · 10 shared papers, 2011–2016 · strength 0.35
  9. Daniel D. Von Hoff · 3 shared papers, 2020–2022 · strength 0.34
  10. Paul Wong · 1 shared paper, 2025 · strength 0.30
  11. Ajay V. Maker · 1 shared paper, 2025 · strength 0.30
  12. Michael Ian D'Angelica · 9 shared papers, 2011–2016 · strength 0.29
  13. Murray F. Brennan · 7 shared papers, 2011–2016 · strength 0.23
  14. Haiyong Han · 2 shared papers, 2020–2022 · strength 0.23
  15. T. Peter Kingham · 5 shared papers, 2012–2016 · strength 0.21
  16. Nanhai G. Chen · 3 shared papers, 2012–2018 · strength 0.17
  17. Vincent M. Chung · 2 shared papers, 2016–2019 · strength 0.16
  18. Fabio Ausania · 1 shared paper, 2023 · strength 0.13
  19. Steven Alan White · 1 shared paper, 2023 · strength 0.13
  20. Riccardo Memeo · 1 shared paper, 2023 · strength 0.13
  21. John B. Martinie · 1 shared paper, 2023 · strength 0.13
  22. Dianrong Xiu · 1 shared paper, 2023 · strength 0.13
  23. Carolina González Abós · 1 shared paper, 2023 · strength 0.13
  24. Gregorio Di Franco · 1 shared paper, 2023 · strength 0.13
  25. Pier Cristoforo Giulianotti · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.